Citation:
Case Rep Neurol. 2022;14:404-7. doi:10.1159/000527358
Abstract:
Eteplirsen is an antisense oligonucleotide used in the treatment of Duchenne muscular dys-
trophy (DMD). The safety of eteplirsen use in individuals with rare comorbid conditions is not
known. We present the case of a 4-year-old boy with a DMD exon deletion amenable to treat-
ment with eteplirsen and comorbid sickle cell anemia. He has received eteplirsen treatment
for 3 years with no clear adverse effects, including no increase in sickle cell crises.
Epub:
Not Epub
Link to Publication:
https://www.karger.com/Article/Pdf/527358
Organism or Cell Type:
human
Delivery Method:
i.v. infusion